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ABSTRACT 
Introduction:  Acute, hospital-acquired anemia (HAA) during admission with AMI is associated 
with higher mortality and worse health status, and often occurs in the absence of recognized 
bleeding.  Diagnostic blood loss from phlebotomy is readily modifiable, but the relationship 
between diagnostic blood loss and HAA is unclear.   
Methods:  We studied 17,676 AMI patients in the Health Facts database who were not anemic at 
admission and did not undergo coronary bypass surgery,  focusing on the development of 
moderate-severe HAA (Hgb decline to < 11 g/dl during hospitalization), since this degree of 
HAA has been shown to be prognostically important.  Health Facts included the lab tests, as well 
as date and time of every blood draw.  Patients’ total diagnostic blood loss was calculated by 
multiplying the number and types of blood tubes drawn by the standard blood volume for each 
tube type.  Hierarchical modified Poisson regression was used to test the association between 
phlebotomy volume and the development of moderate-severe HAA, accouting for clustering by 
hospital site and adjusting for demographics, comorbidities, disease severity and treatment 
variables.  Sensitivity analyses were conducted after excluding patients with documented 
bleeding and after stratifying by length of stay (LOS).  
Results:  Moderate-severe HAA developed in 3,549 patients (20%).  Total diagnostic blood loss 
ranged from 12ml to 1864ml, and mean phlebotomy volume was significantly higher in patients 
with (182±149 ml) vs. without HAA (86.2±55.9 ml, p<0.001).  The risk of developing HAA was 
greater with increasing phlebotomy volume (per 50 ml:  RR 1.17 (95% CI1.13-1.21)).  After 
multivariable adjustment, each 50 ml of blood drawn for laboratory tests was associated with a 
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14% increase in risk of HAA (RR 1.14 (95% CI 1.11-1.17)).  Results were similar in patients 
without documented bleeding (RR 1.14 (95% CI1.11-1.16) per 50 ml) and stratified by LOS 
(LOS ≤ 4 days:  RR 1.30 (95% CI 1.15-1.46) per 50 ml; LOS ≥ 4 days RR 1.11 (95% CI 1.09-
1.14) per 50 ml).   
Conclusion:  
Blood loss from more frequent phlebotomy is independently associated with the development of 
moderate-severe HAA. These findings suggest that HAA may be preventable by implementing 
strategies to limit both the number of blood draws and the volume of blood removed for 
diagnostic testing. 
 
 v 
 
Acknowledgements: 
Thank you to Kimberly J. Reid, MS for your contributions to this project. 
I am indebted to the following faculty for your guidance and stellar teaching during my 
participation in the Master of Science in Clinical Research degree program:  Dr. Sue-Min Lai, 
Dr. Won Choi, Dr. Edward Ellerbeck, Dr. Hung-Wen (Henry) Yeh, Dr. Theresa Shireman, Dr. 
Babalola Faseru, Dr. John Keighley, Dr. Lauren Aaronson and Dr. Niaman Nazir.  I am also 
deeply grateful for the ongoing mentorship, teaching and research opportunities provided by Dr. 
John Spertus, Dr. Mikhail Kosiborod and Mr. Philip Jones at Saint Luke’s Mid-America Heart 
and Vascular Institute.   
I would also like to acknowledge the gracious support of the American Heart Association-PRT 
Outcomes Research Centers, and specifically the generosity of David and Stevie Spina, for the 
opportunity to pursue the AHA-PRT Outcomes Research Fellowship.  I would also like to thank 
the University of Kansas Clinical Research Curriculum Program (K30) and Dr. Edward 
Ellerbeck for the generous tuition support and access to didactic research training at the 
University of Kansas. 
 
 vi 
 
 
Table of Contents 
 
Section       Page 
 
Abstract       iii 
Acknowledgements      v 
Introduction and Background     1 
Methods       5 
Results       11 
Discussion       25 
References        31 
Appendix  – SAS code     36
 1 
 
INTRODUCTION 
Both chronic anemia, which is present at the time of admission to the hospital, and hospital-
acquired anemia (HAA), which is a new-onset anemia that develops during admission with AMI, 
are associated with greater mortality and poorer health status in patients with AMI.1-5 
Unfortunately, chronic anemia often results from chronic inflammation and underlying 
comorbidities such as renal failure and congestive heart failure.  Administration of anemia 
treatments such as erythropoietin analogues effectively increase hemoglobin (Hgb) levels, 
however, they have also been shown to increase risk of stroke and thromboembolism in other 
patient populations.6-8  Similarly, blood transfusion offers at best a short-term benefit but has also 
been shown to increase mortality when administered to AMI patients.9-11  Accordingly, while 
chronic anemia is a marker for patients at risk of poor outcomes, in many cases there are limited 
treatment options with potential to favorably alter risk for adverse events.  
In contrast to chronic anemia, HAA is a new-onset anemia during hospitalization that 
may be preventable by implementing hospital-based strategies to reduce blood loss in high risk 
patients.  Periprocedural bleeding is an important target for such HAA prevention initiatives.  For 
instance, interventions that decrease bleeding risk at the time of percutaneous coronary 
intervention (such as closure devices or the use of alternative anticoagulants such as bivalirudin) 
are likely to reduce the incidence of HAA by reducing bleeding complications.12  However, 
HAA commonly occurs in the absence of bleeding in both AMI patients and in patients admitted 
for percutaneous coronary intervention, suggesting that factors other than documented bleeding 
are important in the etiology of HAA4,13  Although HAA may reflect unrecognized bleeding 
events in some patients, it is likely that development of HAA is multifactorial and related to 
other clinical factors.  
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Several potential risk factors may explain development of HAA in patients who do not 
experience bleeding events.  Acute inflammation related to myocardial infarction and 
comorbidities such as chronic renal disease or congestive heart failure may result in blunted 
hematopoetic response.14,15  As with chronic anemia, however, most of these are not modifiable.    
In contrast, diagnostic blood loss occurs to a varying degree in all patients hospitalized with AMI 
and may be another important driver of HAA.      
Prior studies in other patient populations have linked diagnostic blood loss with 
development of anemia.  Smoller and colleagues studied 100 patients admitted for both medical 
and surgical care settings. They reported that phlebotomy volumes were particularly high in ICU 
settings and high volumes of diagnostic blood loss were more common in patients who received 
blood transfusion.  In this ICU cohort, they reported a mean volume of blood drawn daily of 41 
ml and a mean of 762 ml per hospitalization.16 Similarly, in a retrospective analysis of patients 
with long intensive care unit says, Chant and colleagues found that phlebotomy volume was an 
independent correlate of transfusion requirement.17  More recently, Thavendiranathan reported a 
retrospective, single center study of the relationship between diagnostic blood loss and 
development of anemia including all patients admitted to a general medicine service in an 
academic hospital setting.18  Diagnostic blood loss averaged 75 ml but varied significantly 
(standard deviation 52 ml).  Even after adjusting for relevant confounders, higher phlebotomy 
volume was strongly associated with hemoglobin declines during hospitalization. 
Patients admitted with AMI may be particularly vulnerable to large blood losses from 
diagnostic phlebotomy.  In addition to baseline laboratory investigations necessary to evaluate 
metabolic status, renal function and hemoglobin, AMI patients often have additional lab 
investigations beyond those commonly drawn for patients admitted to general medical wards.  
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For example, serial cardiac biomarker assessments are obtained to assess for ongoing ischemia 
and document the severity of the patients’ myocardial infarction, pre- and post-procedural labs 
are required to assess for blood loss or renal insult in patients undergoing coronary angiography 
and serial electrolyte assessments are often ordered to ensure potassium and magnesium are 
normalized to reduce risk of arrhythmia.   Importantly, this potential risk factor is under the locus 
of control of care providers who can limit scheduled phlebotomy, use pediatric blood tubes in 
place of standard blood collection tubes and relay more heavily on stored serum specimens in 
high risk patients.  These strategies could reduce diagnostic blood loss and also the incidence and 
severity of HAA.19-21  Although reducing diagnostic blood loss is a common-sense intervention 
that may even be cost-saving in AMI care, few studies have evaluated the relationship between 
blood loss from phlebotomy and development of HAA.   
The only prior study we are aware of that studied the relationship between diagnostic 
blood loss and HAA in patients admitted for AMI was published by Thank-Johnson in 1993.22  
The authors found that patients treated with thrombolytics often had larger in-hospital 
hemoglobin declines than controls who did not receive thrombolysis, even in the absence of 
observed bleeding or invasive procedures.  Patients who received thrombolytics also had greater 
phlebotomy volumes over the first 24 hours of hospitalization.  The authors concluded that 
higher phlebotomy volumes were a likely contributors to the larger hemoglobin declines in the 
thrombolysis group.  However, the study was small, represents practice patterns over 20 years 
ago, and no statistical test of the association between phlebotomy and in-hospital hemoglobin 
declines was applied.  It is unclear from this study whether volume of diagnostic blood loss is an 
independent correlate of in-hospital hemoglobin declines after accounting for relevant 
confounders. 
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 Since diagnostic blood loss is a potentially modifiable risk factor for development of 
HAA, we undertook the following study with the goal of describing the relationship between 
diagnostic blood loss and HAA.  Our goals were to quantify diagnostic blood loss in a nationally 
representative cohort of AMI patients and see if the volume of diagnostic blood loss from 
phlebotomy is associated with HAA.  Since this relationship is likely confounded by other 
variables, we also studied whether any crude relationships persisted after multivariable 
adjustment.  The specific aims of the study were to:  
1.  Compare patients who developed HAA to those who do not develop HAA and determine 
the mean/median volume of diagnostic blood loss over the course of the hospitalization, 
average diagnostic blood loss per 24 hours of hospitalization, and on each individual 
hospital day (1-10, respectively). 
2. Describe the variability in diagnostic blood loss volumes across Health Facts hospitals. 
3. Understand the relationship between diagnostic blood loss and development of HAA.  To 
understand whether this is an independent relationship, we built a multivariable 
regression model to understand whether diagnostic blood loss is associated with the 
development of HAA accounting for relevant confounders. 
4. Understand the relationship between the development of HAA and length of stay.  
Specifically, do patients who develop HAA tend to develop it early in the hospital or later 
during the admission?  If we hypothesize that the cumulative burden of ongoing 
diagnostic blood loss may lead to HAA, then we must see that some patients develop 
HAA late in the hospitalization.  Further, we hoped to understand whether the 
relationship between diagnostic blood loss and HAA persisted after stratifying by length 
of hospital stay. 
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5. Perform sensitivity analyses to understand how different assumptions of the volume 
required to fill blood tubes influences the estimated diagnostic blood loss (since the 
available literature reports several different standard blood volumes) and determine how 
implementation of potential strategies to reduce diagnostic blood loss (specifically, using 
pediatric tubes in place of standard phlebotomy tubes) could influence the relationship 
between phlebotomy and HAA.  Finally, since another important risk factor for HAA is 
bleeding, we will repeat our analyses after excluding patients who had known bleeding to 
understand whether our results are consistent in these patients.  
METHODS 
Data Source 
We studied hospital encounters in the Cerner Health Facts database, a large database of 
all AMI admissions to participating hospitals using the Cerner electronic medical record.  Full 
details of the Cerner Health Facts Database have been described previously.23,24  The database 
captures the deidentified data of consecutive AMI encounters.  Included patients had a primary 
discharge diagnosis of AMI as determined by International Classification of Diseases, Ninth 
Revision, Clinical Modification diagnostic codes 410.xx.  Detailed data from admissions between 
January 1, 2000 and December 31, 2008 were collected including hospital characteristics, 
patients’ demographic characteristics (limited to age, gender and race and abstracted from the 
electronic medical records medical records and registration data), medical history and 
comorbidities (using International Classification of Diseases, Ninth Revision, Clinical 
Modification diagnostic codes), laboratory studies (including venous and arterial blood draws 
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and time of phlebotomy events), in hospital medications and procedures, in-hospital 
complications and inpatient mortality.   
Study Population 
The total population included in this database represents 61,149 encounters from a total 
of 53,659 unique patients.  To avoid including patients readmitted after recent AMI who may 
have residual HAA from the previous admission, we limited our cohort to the first AMI 
encounter for each patient.  Among these 53,659 patients, we further confirmed the patient was 
admitted for AMI by excluding patients without at least 1 abnormal cardiac biomarker (troponin 
or CK-MB) during the admission (n=13,900 patients) and those who were discharged within the 
first 24 hours after admission (n= 1,337 patients).  We also excluded 81 patients transferred from 
other acute care facilities or from hospice, since full data on processes of care were not available 
on patients transferred from another acute care facility and goals of care for patients on hospice 
may differ from the overall population.  Additionally, we excluded 57 patients from hospitals 
with small enrollments (<20 patients) and 392 patients with lengths of stay greater than 31 days, 
since these patients’ data are generalizable to very few patients admitted with AMI. 
Exclusion criteria included coronary artery bypass grafting during the index admission 
(n=3,990), since post-bypass anemia is attributable to the surgery itself and is associated with 
distinct long term outcomes.4 Patients who did not have hemoglobin assessed within the first 24 
hours of the admission (n=2,225), those without at least 2 hemoglobin assessments during their 
hospitalization (n=3,577), and those who were anemic at admission (below diagnostic thresholds 
for anemia on initial Hgb, n=10,424) were also excluded yielding a final analytic cohort of 
17,676 patients with AMI and without anemia at admission from 57 hospitals. 
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Anemia and Bleeding Definitions  
 Patients were classified as having hospital-acquired anemia if they had a normal 
admission hemoglobin but nadir hemoglobin (defined as each patients’ lowest hemoglobin value 
over the course of their hospitalization) declined below diagnostic thresholds for anemia.  
Anemia was defined using age, gender, and race specific criteria was described by Beutler and 
Waalen as a hemoglobin value less than 13.7 g/dl for white men aged 20 to 59, 13.2 g/dl for 
white men ≥ 60 years, 12.9 g/dl for black men aged 20-59, 12.7 g/dl for black men ≥ 60 years, 
12.2 g/dl for white women and 11.5 g/dl for black women. This classification is based upon 
analyses of large, modern cohorts and more accurately identifies anemia than the World Health 
Organization definition (WHO).25  There were few patients who reported a race other than white 
or black.  For these patients, we applied the Beutler and Waalen criteria for blacks since there a 
fewer data to guide how the diagnostic threshold for anemia varies in other races. Anemia was 
classified as mild (diagnostic threshold>Hgb > 11.0 g/dl) or moderate-severe (Hgb ≤11.0 g/dl) 
consistent with prior work.4  In contrast to moderate-severe hospital acquired anemia, mild HAA 
has not been shown to be independently associated with increased mortality.4  Because it has not 
been shown to be prognostically important, whereas mild HAA has not been shown to be 
associated with poor outcomes, moderate-severe HAA was selected as the outcome for the 
present study.  Since the outcome of interest was moderate-severe HAA, the bleeding definition 
did not alter categorization of patients as having moderate-severe HAA since differences 
between the Beutler and Waalen and the WHO anemia definitions only influence the proportion 
of patients with mild HAA vs. no HAA.  Bleeding events were identified by reviewing all ICD-9 
codes and including any that reflected an in-hospital bleeding episode in creation of an “in-
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hospital bleeding” variable.  We subdivided the type of bleeding (intracranial, retroperitoneal, 
gastrointestinal and miscellaneous). 
Ascertainment of Diagnostic Blood Loss 
 The date and time of every blood draw and the laboratory test that were collected with 
each phlebotomy event were recorded in the Cerner electronic medical record and are available 
in the Health Facts database.  Using these data, we identified the number and types of blood 
tubes that would be needed to complete the laboratory tests reported in the medical record.  All 
laboratory tests obtained at the time of each blood draw that could have been run off of a 
particular type of blood tube will be assumed to have been run off of a single tube. Each type of 
tube was assigned a conservative estimate of typical blood draw volume from the literature. 
Hematology tubes were assigned a volume of 5 ml, coagulation laboratory tubes 4.5 ml, 
chemistry/miscellaneous laboratory tubes 5 ml,  arterial blood gas tubes 2 ml and blood cultures 
10 ml based on estimates from prior literature.17  For each patient, we multiplied these blood 
volumes by the number of type of blood tubes collected during each patient’s hospitalization to 
arrive at total volume of blood drawn for diagnostic tests during the hospitalization.  We also 
calculated the average phlebotomy volumes per 24 hour period during each patient’s 
hospitalization and mean phlebotomy volumes on the each of the first through 10th days of 
hospital admission.  For the latter analyses, only patients who remained hospitalized on each 
respective day were included in the denominator. 
Statistical Analyses 
Baseline patient characteristics, laboratory values, in-hospital treatments and in-hospital 
complications of patients who developed moderate-severe HAA were compared to those who did 
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not develop anemia or had mild HAA.  For descriptive purposes, we presented categorical data 
as frequencies and differences between groups were compared using chi-square tests.  
Continuous variables were reported as the mean ± standard deviation and differences were 
compared using independent t-tests.  The Wilcoxon rank-sum was used to compare variables that 
have a skewed distribution, and results were reported as the median and interquartile range.   
When comparing diagnostic blood loss volumes across Health Facts hospitals, we 
generated shrinkage estimates to account for smaller enrollments into Health Facts from small 
hospitals.  This approach pulls estimates from smaller hospitals toward the overall mean.  
Estimates were generated from a linear model which included site as a random effect and no 
other independent variables. 
We used hierarchical multivariable regression, including hospital site as a random effect 
to account for clustering within hospitals.  The outcome of interest is prevalent based on prior 
literature; accordingly, we used a relative risk regression strategy using Poisson regression with 
robust error variance.26   To identify the independent association between phlebotomy volume 
and development of moderate-severe HAA, we adjusted for key demographic, clinical and 
treatment variables that we identified a priori based on clinical experience.  These variables 
represent likely confounders that could obscure the independent association between diagnostic 
blood loss and HAA.  For instance, women, older patients, and those with chronic kidney disease 
or diabetes are more likely to develop HAA, and could undergo more frequent blood draws as 
clinicians attempt to monitor their laboratories more closely.  The variables included were key 
demographics (age, gender and race [Caucasian vs. other]), clinical characteristics (history of 
chronic kidney disease, congestive heart failure, hypertension, diabetes and prior myocardial 
infarction) and MI type and treatments (ST-elevation MI vs. non-ST-segment elevation MI, 
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thrombolytics, in-hospital cardiac catheterization or PCI, use of aspirin, thienopyridines, 
glycoprotein IIb/IIIa inhibitors, thrombolytics, heparin, warfarin, ACE inhibitors/ARBs, beta 
blockers, statins and bivalirudin).  We also adjusted for in-hospital complications that could 
confound the apparent association between diagnostic blood loss for phlebotomy and 
development of moderate-severe HAA.  For instance, patients with acute renal failure, 
cardiogenic shock and mechanical ventilation would be more likely to receive frequent blood 
draws.  Accordingly, we adjusted for each of these in the model.   We also tested for statistically 
and clinically important interactions between model covariates and the primary exposure 
variable of diagnostic blood loss from phlebotomy.  A priori two-way interactions between 
diagnostic blood loss volume and race, mechanical ventilation, chronic kidney disease, gender 
and cardiac catheterization or PCI were also tested.  The calibration of the model was assessed 
by plotting the mean predicted risk of developing moderate-severe HAA within each decile of 
risk of HAA vs. the observed moderate-severe HAA rates.     
Missing Data 
Missing data were minimal and the data that were missing were assumed to be missing at 
random.  This included 267 missing observations for initial creatinine and no more than 1 
missing value for the other covariates in our model.   Accordingly, we used multiple imputation 
with IVEWARE software to impute these values to allow inclusion of the entire analytic cohort 
in the modeling.   
Sensitivity analyses 
Several sensitivity analyses were conducted to confirm the robustness of our findings.   
Varying estimates of the volume of blood needed to fill each standard tube have been reported in 
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the literature, and hospitals are likely to use different standard volumes depending on equipment 
and the facility’s awareness and support of blood conservation efforts.  Therefore, we repeated 
our calculation of diagnostic blood loss after assuming alternative estimated volumes from the 
literature.16,27-29   We also used estimates of blood draw volumes using pediatric tubes20 to 
estimate how this potential intervention would influence the volume of phlebotomy if pediatric 
tubes were used in place of standard-volume blood tubes.  Estimates for tube volume derived 
from this paper were 1.2 ml for CBC (EDTA tube), 1.4 ml for citrate tubes (coagulation studies), 
and 1.1ml for other tube types.  Moreover, since phlebotomy volume and length of stay are likely 
to be strongly associated, we conducted another sensitivity analyses stratifying patients by length 
of stay (less than or equal to 4 days, representing the duration of many uncomplicated AMI 
admissions, versus greater than 4 days).  To to assess the relationship between diagnostic blood 
loss and development of HAA in the absence of documented bleeding, we excluded all patients 
with known bleeding and repeated our primary analyses.  Additionally, since phlebotomy 
volumes reported in the literature are variable, we conducted sensitivity analyses around the 
estimated volume of blood needed to fill each type of tube.  Specifically, analyses were repeated 
using various published estimates of blood volume required for each tube type.16,27-29  
 
RESULTS 
Baseline Characteristics, Frequency of HAA and In-Hospital Hemoglobin Declines 
 One out of every 5 patients admitted with AMI developed moderate-severe HAA (3,551 
patients (20.1%)).  Patient characteristics of those who developed moderate-severe HAA are 
compared to those who did not Table 1.   
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Table 1:  Patient Characteristics of Patients with and Without Moderate-Severe Hospital 
Acquired Anemia 
  
Moderate-severe HAA 
P-Value 
Yes 
(n = 3,551) 
No 
(n = 14,125) 
Age (mean±SD) 71.9 ± 13.0 64.5 ± 14.5 < 0.001 
Race (% Caucasian) 2933 (82.6%) 12314 (87.2%) < 0.001 
Gender (% female)  2481 (69.9%) 4651 (32.9%) < 0.001 
Length of stay (Median (IQR)) 6.5 (4.1, 10.1) 3.5 (2.5, 5.0) < 0.001 
Dyslipidemia 1054 (29.7%) 7056 (50.0%) < 0.001 
Heart failure 1377 (38.8%) 2995 (21.2%) < 0.001 
Hypertension 1793 (50.5%) 7833 (55.5%) < 0.001 
History of percutaneous coronary 
intervention 
109 (3.1%) 923 (6.5%) < 0.001 
Chronic kidney disease 454 (12.8%) 648 (4.6%) < 0.001 
Peripheral arterial disease 101 (2.8%) 293 (2.1%)   0.005 
IV Heparin 2671 (75.2%) 10286 (72.8%)   0.004 
Diabetes 1134 (31.9%) 3566 (25.2%) < 0.001 
History of coronary artery bypass 
surgery 
97 (2.7%) 642 (4.5%) < 0.001 
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Moderate-severe HAA 
P-Value 
Yes 
(n = 3,551) 
No 
(n = 14,125) 
Prior myocardial infarction 131 (3.7%) 909 (6.4%) < 0.001 
Current smoking 483 (13.6%) 4635 (32.8%) < 0.001 
History of Stroke/transient ischemic 
attack 
167 (4.7%) 320 (2.3%) < 0.001 
Acute renal failure 513 (14.4%) 510 (3.6%) < 0.001 
Bleeding event from ICD9 diagnosi
s codes 
499 (14.1%) 436 (3.1%) < 0.001 
Cardiogenic shock 336 (9.5%) 305 (2.2%) < 0.001 
In hospital mechanical ventilation 390 (11.0%) 422 (3.0%) < 0.001 
Bleeding event type from ICD9 dia
gnosis codes 
     Miscellaneous site 
     GI bleed 
     Intracranial 
  
 
290 (58.1%) 
196 (39.3%) 
13 (2.6%) 
  
 
301 (69.0%) 
100 (22.9%) 
35 (8.0%) 
< 0.001 
ST-Elevation MI 1547 (43.6%) 6127 (43.4%)   0.840 
Non ST-Elevation MI 1874 (52.8%) 7543 (53.4%)   0.503 
ACE inhibitor or ARB 2431 (68.5%) 9242 (65.4%) < 0.001 
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Moderate-severe HAA 
P-Value 
Yes 
(n = 3,551) 
No 
(n = 14,125) 
Thienopyridine 2379 (67.0%) 9924 (70.3%) < 0.001 
Aspirin 3091 (87.1%) 12304 (87.1%)   0.952 
Beta blockers 3049 (85.9%) 11957 (84.7%)   0.066 
Diuretics 1935 (54.5%) 4376 (31.0%) < 0.001 
Glycoprotein IIa/IIIb inhibitor 1702 (47.9%) 7213 (51.1%) < 0.001 
Bivalirudin 129 (3.6%) 656 (4.6%)   0.009 
Statin 2301 (64.8%) 9833 (69.6%) < 0.001 
Thrombolytics 184 (5.2%) 575 (4.1%)   0.003 
Warfarin 507 (14.3%) 1295 (9.2%) < 0.001 
In hospital coronary angiogram 2253 (63.4%) 10230 (72.4%) < 0.001 
In hospital percutaneous coronary 
intervention 
1719 (48.4%) 7970 (56.4%) < 0.001 
Initial hemoglobin (g/dl, mean±SD) 13.64 ± 1.15 14.71 ± 1.26 < 0.001 
Minimum hemoglobin (g/dl, 
mean±SD) 
9.78 ± 1.14 13.09 ± 1.22 < 0.001 
Final hemoglobin (g/dl, mean±SD) 10.67 ± 1.05 13.41 ± 1.30 < 0.001 
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Moderate-severe HAA 
P-Value 
Yes 
(n = 3,551) 
No 
(n = 14,125) 
Time from admission to moderate-
severe HAA (days) 
2.7 ± 2.6 - - 
Admission creatinine 1.4 ± 1.2 1.2 ± 0.7 < 0.001 
Continuous variables compared using Student's T-test. 
Categorical variables compared using chi-square or Fisher's exact test. 
 
Patients who developed moderate-severe HAA were older and greater proportions were female 
and non-white race.  Several comorbidities were more common in those who developed 
moderate-severe HAA including heart failure, chronic renal failure and diabetes.  In contrast, 
dyslipidemia, hypertension and prior PCI or CABG were less likely in those with moderate-
severe HAA.  Several important differences in in-hospital treatments were noted.  Fewer 
moderate-severe HAA patients received thrombolytics,  glycoprotein IIb/IIIa inhibitors and 
bivalirudin and a greater proportion received heparin and warfarin.  Moderate-severe HAA 
patients less frequently had coronary angiography or percutaneous coronary intervention.  They 
were also more likely to develop acute complications of cardiogenic shock and acute renal 
failure.  Consistent with more complicated admissions in the moderate-severe HAA group, the 
median length of stay was 6.5 days (IQR 4.1, 10.1) among patients with moderate-severe HAA 
vs. 3.5 days (IQR 2.5, 5.0) for patients with mild or no HAA (p<0.001).   The mean hemoglobin 
declined during hospitalization in both groups, with greater declines in those with moderate-
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severe HAA (3.86 g/dl ± 1.64 vs. 1.62± 1.09, p<0.001).  In-hospital bleeding was significantly 
more common in patients with moderate-severe HAA (14.1% vs. 3.1%, p<0.001).   
Diagnostic Blood Loss 
 Mean, median and range of diagnostic blood loss during the course of hospitalization and 
per 24 hours are presented in Table 2, as well as the breakdown of phlebotomy volume per type 
of blood tube drawn.  Mean blood loss from phlebotomy was nearly 100 ml higher over the 
course of the hospitalization among patients who developed moderate-severe HAA (182.1±148.5 
ml vs. 86.2±55.9 ml, p<0.001), while mean blood loss per 24 hours hospitalized was slightly 
greater in those with moderate-severe HAA (25.7±43.2 vs. 23.5±25.6, p<0.001).  Accordingly, 
mean differences in total diagnostic blood loss volumes largely reflect differences in length of 
stay and ongoing daily blood draws during prolonged hospitalizations.   
Table 2:  Diagnostic Blood Loss Estimates During Hospitalization with Acute Myocardial 
Infarction 
 
  
Moderate-severe HAA 
P-Value 
Yes 
(n = 3,551) 
No 
(n = 14125) 
Total Diagnostic Blood Loss (ml)                   
      Mean±SD 
      Median (IQR) 
 
182.1 ± 148.5 
137.0 (91.0, 221.0) 
 
86.2 ± 55.9 
70.5 (51.5, 102.5) 
< 0.001 
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Moderate-severe HAA 
P-Value 
Yes 
(n = 3,551) 
No 
(n = 14125) 
Diagnostic Blood Loss per 24 hours (ml) 
      Mean±SD 
      Median (IQR) 
 
25.7 ± 43.2 
21.9 (16.3, 28.8) 
 
23.5 ± 25.6 
20.8 (15.7, 27.3) 
< 0.001 
Range of Diagnostic Blood Loss (ml) 
     Min 
     Max 
  
20.0 
1864.0 
  
12.0 
732.0 
< 0.001 
Total Number of Blood tubes (mean±SD) 40.5 ± 33.2 19.3 ± 12.2 < 0.001 
Blood tubes per 24 hours (mean±SD) 5.7 ± 7.8 5.2 ± 4.9 < 0.001 
Range of Number of Blood tubes 
     Min 
     Max 
  
4.0 
443.0 
  
3.0 
172.0 
< 0.001 
Blood Loss from Arterial Blood Gas 
(mean±SD) 
18.3 ± 19.7 7.7 ± 6.9 < 0.001 
Blood Loss from Chemistries (mean±SD) 69.6 ± 63.3 35.8 ± 23.5 < 0.001 
Blood Loss from Coagulation labs 
(mean±SD) 
26.6 ± 28.5 15.3 ± 16.8 < 0.001 
Blood Loss from CBCs (mean±SD) 47.4 ± 38.7 21.3 ± 12.5 < 0.001 
Blood Loss from Blood Cultures (mean±SD) 20.3 ± 36.4 6.1 ± 18.0 < 0.001 
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When diagnostic blood loss was estimated for each hospital day, the mean diagnostic blood loss 
was highest on the first two hospital days and declined over subsequent days (Figure 1).   
Figure 1:  Mean Volume of Diagnostic Blood Loss On Each Day From Hospital Day 1 Through 10 
 
Mean blood loss from phlebotomy was nearly 100 ml higher over the course of the 
hospitalization among patients who developed moderate-severe HAA (182.1±148.5 ml vs. 
86.2±55.9 ml, p<0.001), while mean blood loss per 24 hours hospitalized was slightly greater in 
those with moderate-severe HAA (25.7±43.2 vs. 23.5±25.6, p<0.001).  Accordingly, mean 
differences in total diagnostic blood loss volumes largely reflect differences in length of stay and 
ongoing daily blood draws during prolonged hospitalizations.  When diagnostic blood loss was 
estimated for each hospital day, the mean diagnostic blood loss was highest on the first two 
hospital days and declined over subsequent days (Figure 1).   
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Variability in Diagnostic Blood Loss Across Hospitals 
There was important variability in the estimated diagnostic blood loss from phlebotomy 
across Health Facts hospitals.  Regardless of HAA status, the mean volume of diagnostic blood 
loss from phlebotomy varied between 53.8 ml and 145.2 ml.  After adjusting for the size of each 
hospital’s patient population, this range was 69.6 ml (95% CI 61.1-78.1 ml) to 144 ml (95% CI 
138.0-150.0 ml).  There was even greater variability among those with moderate-severe HAA.  
The unadjusted total diagnostic blood loss ranged from 66.5ml to 400.1 ml while shrinkage 
adjusted values ranged from 129.0 ml (95% CI 100.3 ml-157.7 ml) to 244.2 ml (95% CI 183.4 
ml- 305.0 ml) across hospitals. 
  
Multivariable Model for Development of Moderate-Severe HAA 
The multivariable modified Poisson model for development of moderate-severe HAA is 
presented in Table 3.  
Table 3:  Multivariable Model Predicting Moderate-Severe HAA 
Variable 
Relative 
Risk Lower CI Upper CI p-value
Diagnostic blood loss (per 
50 ml increase) 
1.14 1.13 1.15 <.0001
Age (10 year increase) 1.24 1.21 1.28 <.0001
Female 2.97 2.75 3.20 <.0001
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Variable 
Relative 
Risk Lower CI Upper CI p-value
Non-Caucasian 1.30 1.19 1.43 <.0001
ST elevation MI 1.16 1.07 1.25 .0001
Acute Renal Failure 1.22 1.09 1.36 0.0003
Heparin 1.13 1.04 1.23 0.002
Cardiogenic Shock 1.14 0.99 1.30 0.0625
In hospital Cath or PCI 1.15 1.04 1.26 0.005
Glycoprotein IIb/IIIa 
inhibitor 
1.22 1.13 1.33 <0.001
Bivalirudin 0.86 0.72 1.03 0.106
Antiplatelet 1.04 0.95 1.14 0.351
Beta-Blocker 1.04 0.94 1.16 0.445
Statin 0.98 0.90 1.06 0.615
ACE/ARB 1.15 1.06 1.24 0.0007
Aspirin 0.91 0.81 1.03 0.126
Thrombolytics 1.07 0.92 1.26 0.378
Mechanical ventilation 1.41 1.26 1.58 <.0001
CKD 1.51 1.36 1.69 <.0001
Prior MI 0.80 0.67 0.95 0.013
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Variable 
Relative 
Risk Lower CI Upper CI p-value
Diabetes 1.10 1.02 1.18 0.0005
Heart failure 1.06 0.98 1.14 0.0965
Hypertension 0.87 0.81 0.93  <.0001
 
 No interactions were included in the final model.  Interactions of diagnostic blood loss volume 
by race, mechanical ventilation and cardiac catheterization or PCI were not statistically 
significant.  Interactions of chronic kidney disease and gender with volume of diagnostic blood 
loss were statistically significant but did not result in clinically important differences in the 
relative risk of developing moderate-severe HAA.  The model had excellent capacity to 
discriminate moderate-severe HAA with a c-statistic of 0.831, and model calibration was 
acceptable (Figure 2). 
Figure 2:  Plot of Mean Predicted Risk of Moderate-Severe HAA within Deciles of Predicted Risk 
vs. Observed Rates of Moderate-Severe HAA 
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Relationship Between Diagnostic Blood Loss and Development of Moderate-Severe HAA 
 The risk of developing moderate-severe HAA was highest on the first hospital day, when 
1 in 5 patients developed moderate-severe HAA (Figure 3). 
Figure 3:  Proportion of Patients Developing Moderate-Severe HAA on Hospital Days 1 Through 
10 
 23 
 
 
 On hospital days 2 through 10, the proportion of patients who developed new moderate-severe 
HAA ranged between 11.1% and 13.6%.  There was a significant unadjusted relationship 
between volume of diagnostic blood loss and development of moderate-severe HAA.  Each 50 
ml of blood drawn was associated with a 17% increase in risk of HAA (RR 1.17, 95% CI 1.14-
1.21, p<0.001).  After adjusting for demographic and clinical confounders, diagnostic blood loss 
remained an independent predictor of moderate-severe HAA (per 50 ml:   RR 1.14, 95% CI 1.11-
1.17, p<0.001). 
Sensitivity Analyses  
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Our first sensitivity analysis focused on the influence of length of stay on the association 
between diagnostic blood loss and moderate-severe HAA.  There was a significant interaction 
between length of stay and diagnostic blood loss (p<0.001). Accordingly, we stratified these 
analyses by stratified by of length of stay.  Among patients with a length of stay of 4 days or less 
(N=9,461), the risk of HAA was greater with increasing diagnostic blood loss (per 50 ml:  RR 
1.30, 95% CI 1.15-1.46, p<0.001) than in patients with lengths of stay greater than 4 days 
(N=8215; per 50 ml:  RR 1.11, 95% CI 1.09-1.14, p<0.001).   
Results of several other sensitivity analyses were consistent with our primary findings.  
After excluding patients who suffered documented bleeding episodes (N=16741), the risk of 
HAA remained unchanged (RR 1.14, 95% CI 1.11-1.16, p<0.001).  Estimates of total diagnostic 
blood loss generated by varying the volume of blood required to fill each tube based upon 
alternative reports from the prior literature are presented in Table 4.  
Table 4:  Estimated Diagnostic Blood Loss Across Range of Potential Tube Volumes 
 Study Reporting 
Blood Tube 
Volumes 
Diagnostic blood loss:  
Moderate‐Severe HAA 
(mean±SD) 
Diagnostic Blood 
loss:  Mild HAA or no 
HAA (mean±SD) 
Risk of Moderate‐
Severe HAA (per 50 
ml) 
Smoller, et. al, 
19869 
233.0±187.0  114.5±69.6  1.11 (95% CI 1.08‐
1.14) 
Wisser, et. al., 
200320 
144.5±122.4  67.8±46.5  1.17 (95% CI 1.13‐
1.21) 
Shaffer, 200721  140.1±115.7  67.8±46.5  1.19 (95% CI 1.15‐
1.23) 
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Pabla et. al., 
200922* 
155.8±128.6  73.0±48.8  1.17 (95% CI 1.13‐
1.20) 
 
Among patients who developed moderate-severe HAA, the estimated total phlebotomy volume 
ranged from 140.1±115.7 ml using the most conservative estimates of blood volume required to 
fill standard tubes to 233.0±187.0 ml using the largest blood volume estimates from prior 
literature.  The relative risk of developing moderate-severe HAA remained similar when using 
these different estimates of phlebotomy volumes. If pediatric blood tubes were used in place of 
standard tubes for all blood draws in Health Facts, the mean estimated diagnostic blood loss 
volume in the overall cohort would decline to 35.5 ± 39.0 (65.3 ± 62.2 ml (range 4ml to 689 ml) 
in those with moderate-severe HAA and 28.0 ± 25.5 ml (range 3.4 to 433 ml) in those with mild 
or no HAA). 
Discussion 
 In this large, cohort of unselected AMI patients from hospitals across the United States, 
diagnostic blood loss from phlebotomy was substantial and greater use of phlebotomy was 
independently associated with a higher risk of developing moderate-severe HAA.  Diagnostic 
blood loss during hospitalization with AMI varied dramatically within this cohort and also varied 
across hospitals, suggesting that process of care differences may influence the volume of blood 
taken for diagnostic tests.  Importantly, we found that the mean daily volume of diagnostic blood 
loss remained consistent even during prolonged hospitalizations, suggesting that the common 
clinical practice of daily, scheduled phlebotomy can lead to large cumulative blood loss for 
patients who experience long hospitalizations.  Accordingly, a large fraction of patients’ total 
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diagnostic blood loss volumes reflect differences in length of stay and ongoing daily blood draws 
during prolonged hospitalizations, which may represent a preventable cause of HAA.  Moreover, 
we found that on each hospital day over 10% of patients who began the day with a normal Hgb 
developed HAA, confirming an ongoing risk of HAA throughout the course of hospitalization 
with AMI. Finally, the association between amount blood collected for diagnostic tests and the 
development of moderate-severe HAA was significant, and remained robust after multivariable 
adjustment and in several sensitivity analyses. 
 Prior studies have shown that HAA and in-hospital Hgb declines are common and are 
associated with poor post-AMI outcomes, including higher mortality and worse health 
status.4,13,30    In our study, HAA developed in over half of patients admitted for AMI who did 
not have baseline anemia or undergo coronary bypass surgery, 1 in 5 patients developed 
moderate-severe HAA.  Several mechanisms play a role in development of HAA.  Although 
some of these are not modifiable (age, gender, chronic kidney disease, inflammation in the 
setting of AMI),4,31 two are clearly under the locus of control of healthcare providers – 
prevention of periprocedural bleeding and limitation of diagnostic blood loss from phlebotomy.  
Alternative anticoagulants such as bivalirudin, closure devices, and radial access at the time of 
coronary angiography all reduce the incidence of periprocedural bleeding.12,32-34  However, no 
clear bleeding event is identified in many patients who develop HAA.4,13  Although phlebotomy 
has been suggested as a cause of in-hospital Hgb declines in AMI patients,22 no studies have 
established this relationship.  Our study is the first to directly assess the association between 
diagnostic blood loss and HAA, and leverages a large, contemporary cohort reflecting real world 
patient care, and included detailed data on the number and timing of blood draws. Our finding 
that diagnostic blood loss was often substantial was an independent correlate of higher risk of 
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moderate-severe HAA sheds important light on a potentially modifiable risk factor for moderate-
severe HAA.    It is important that future HAA prevention efforts focus on multi-modal 
interventions, and limiting diagnostic blood loss may be an important component of these efforts.   
Our findings have important clinical implications.  We found that, on average, diagnostic 
blood loss remains relatively constant throughout the course of patients’ hospital stays after the 
first two days of hospitalization.  The majority of diagnostic evaluation and therapeutic 
interventions often occur relatively early during hospitalization with AMI, and it is likely that 
much of the blood drawn later in long hospitalizations represents routine, scheduled lab draws 
that could lead to substantial blood loss.  Although much of this phlebotomy may be 
unnecessary, few data have linked this practice to adverse outcomes, but our findings indicate 
greater use of phlebotomy is an important risk factor for HAA.  Measures to reduce unneeded 
blood draws could limit the development and severity of HAA with no additional cost to the 
hospital (using stored serum samples) and potential cost savings (eliminating unnecessary, 
scheduled blood draws), while also reducing patient discomfort and potentially risk for HAA.   
Greater use of pediatric tubes in high risk individuals who require diagnostic testing may also 
reduce diagnostic blood loss.  We found that estimates of blood loss from phlebotomy were 
dramatically lower when estimated using blood volumes required to fill pediatric tubes, 
highlighting a potentially promising intervention to limit diagnostic blood loss.  
The finding that high diagnostic blood loss volumes are common over the course of AMI 
hospitalizations also warrants further discussion.  Among patients who developed moderate-
severe HAA, the mean estimated phlebotomy volume was 182 ml.  This equivalent to nearly half 
a unit of whole blood, and while significant, is likely one contributor among several others in the 
development of HAA.  Moreover, many patients had modest diagnostic blood losses and smaller 
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in-hospital hemoglobin declines, implementing strategies that reduce unneeded, scheduled 
phlebotomy could have other benefits including cost savings and reduced patient discomfort.       
Our data underscore the importance of studying comprehensive interventions, that go beyond 
focusing only on reducing bleeding, to prevent in hospital hemoglobin declines. 
Although our study focused on the association between diagnostic blood loss and 
moderate-severe HAA, we found in prior work that HAA often developed in the absence of 
documented bleeding despite careful, prospective collection of bleeding data.4  The question 
remains - is this a reflection of undocumented bleeding episodes or other factors.  While it may 
be common that minor bleeding episodes are underreported, these episodes have not been shown 
to be prognostically important and are unlikely to result in the large Hgb declines required to 
reach diagnostic thresholds for moderate-severe HAA.  Bleeding prevention should clearly be an 
important focus of HAA prevention efforts, but our findings suggest that phlebotomy is also an 
important factor in the development of moderate-severe HAA that may be a cause of HAA both 
in the presence and absence of bleeding.   
Limitations 
 Several potential limitations of our study should be considered in the interpretation of 
these data.  Our calculation of phlebotomy volume relied on estimates of the amount of blood 
required for each blood tube.  These estimates are consistent with prior literature, and we 
included several conservative assumptions in our calculations (we did not account for wasted 
blood during blood draws, assumed only 1 tube was drawn when many labs drawn at the same 
time could have potentially been run off of only 1 tube but may have required several tubes of 
blood).  Moreover, we conducted sensitivity analyses in which we used alternative volumes for 
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the volume of blood required for each tube, and still found that diagnostic blood loss was 
substantial.  Similarly, different hospitals may have different standard required blood volumes to 
fill each tube, and some may use pediatric tubes in select adult patients.  Future studies with 
prospective collection blood draw volume are needed to further confirm our findings.  We were 
also unable to assess the impact of hemodilution from administration of intravenous fluids or 
from fluid retention in the setting of acute heart failure on Hgb concentrations.  However, since 
large Hgb declines are usually required to develop moderate-severe HAA, hemodilution likely 
had little effect on development of this grade of HAA.  Our assessments of hemoglobin reflected 
clinical practice and therefore were not drawn at protocol driven intervals for each patient.  
Although there was variability in the number and timing of Hgb assessments, these data are 
generalizable to real-world clinical practice where these labs are obtained at the discretion of the 
treating physician.   The Health Facts database lacks long-term patient follow-up, and 
accordingly we were unable to confirm the impact of diagnostic blood loss on long-term 
outcomes.  Although the literature supports a strong association between HAA and long-term 
outcomes, further study of the impact of diagnostic blood loss on long-term mortality and health 
status are needed.  Finally, given the retrospective nature of these analyses residual confounding 
cannot be excluded and no causal inference can be drawn from these observational data.   
Conclusions 
In conclusion, blood loss from more frequent phlebotomy is often significant in patients 
admitted with AMI and is independently associated with the development of moderate-severe 
HAA.  Over ten percent of patients who had not previously developed moderate-severe HAA 
developed new moderate-severe HAA on each hospital day, even late in the course of 
hospitalization.  This reinforces the potential importance of ongoing blood loss and the 
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cumulative effect of large volumes of diagnostic blood loss over the course of prolonged 
hospitalizations.  This is further underscored by finding that diagnostic blood loss from 
phlebotomy remains independently associated with development of moderate-severe HAA in 
patients with long lengths of stay after stratifying by length of hospitalization. These findings 
suggest that HAA may be preventable by implementing blood conservation strategies that limit 
both the number of blood draws and the volume of blood removed for diagnostic testing.  Further 
studies are needed to determine whether these measures reduce the incidence of HAA and 
improve clinical outcomes. 
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Appendix 
Example SAS code: 
Note:  Base code presented below.  Multiple sensitivity analyses conducted with the same base 
data/models/code.  Most variables were already coded for a prior project – code not presented. 
 
libname hf 'c:\work\temp s\health facts data'; 
libname phleb 'C:\Documents and Settings\p08806\Desktop\KU MS-CR 
Classes\Thesis Materials'; 
options fmtsearch=(hf phleb source); 
options nofmterr; 
 
proc format lib=phleb; 
 value yesno 1='(1) Yes' 0='(0) No';  
 value bleedtp 
  1 = '(1) Misc site' 
  2 = '(2) GI bleed' 
  3 = '(3) Retroperitoneal' 
  4 = '(4) Intracranial' 
  5 = '(5) Intraocular'; 
 value sevdichot 
  0 = '(0) Mild/None' 
  1 = '(1) Moderate/Severe'; 
run; 
 
options fmtsearch=(hf phleb) nofmterr;  
 
 
*frequency of mod-severe HAA; 
 
proc freq data=phleb.bw_091610; 
tables modsevhaa ; 
run; 
 
*histogram of phlebotomy ml; 
 
PROC UNIVARIATE DATA=phleb.bw_091610 NOPRINT; 
 
  VAR totalml; 
 
  HISTOGRAM /NORMAL (COLOR=RED W=5) NROWS=3; 
 
RUN; 
 
*descriptives for Table 1.  We used the standard MAHI macro to generate this 
to spare the tedium 
given the large number of variables.  These wont print out on my laptop so 
I've provided the RTF  
files separately; 
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ods rtf file="C:\Documents and Settings\p08806\Desktop\KU MS-CR 
Classes\Thesis Materials\table1 &rundate..rtf";  
 
title1 'descriptives overall'; 
%wordfmt; 
%report (format=rtf);  
  %set(data=phleb.BW_analysis_091610,showmiss=t); 
  %table; 
 %freq(admitted_yr); %freq(discharge_year);  
 
%stat(min_hgb,stat=mediqr,ndec=2);  
%stat(min_hgb,ndec=2); 
%stat(mean_hgb,stat=mediqr,ndec=2); 
%stat(mean_hgb,ndec=2);  
%stat(adm_hgb,stat=mediqr,ndec=2); 
%stat(adm_hgb,ndec=2); 
%stat(final_hgb,stat=mediqr,ndec=2);  
%stat(final_hgb,ndec=2);  
%stat(adm_min_change,ndec=2);%stat(adm_min_change,stat=mediqr,ndec=2); 
%stat(num_hemoglobin_labs); %stat(num_hemoglobin_labs,stat=mediqr); 
 
%freq(HAA);%freq(modsevhaa); 
%stat(timetohaa_modsev); %stat(timetohaa_modsev,stat=mediqr); 
%freq(severity); %freq(severity_cat); 
%stat(totalml);%stat(totalml,stat=mediqr);%stat(mlperday); 
%stat(mlperday,stat=mediqr);  
 
%stat(num_phleb_labs); %stat(mean24hr); 
 
%stat(totalml,stat=min max);%stat(mlperday,stat=min max); 
%stat(num_phleb_labs,stat=min max); 
 
%stat(numtube_A); %stat(numtube_C);  %stat(numtube_CL); %stat(numtube_H); 
%stat(numtube_BC); 
%stat(totalml_A); %stat(totalml_C);  %stat(totalml_CL); %stat(totalml_H); 
%stat(totalml_BC); 
 
%freq(bleeding_event);%freq(bleeding_event_type); 
 
%stat(AGE); %freq(RACE);%freq(caucasian); 
%freq(raceblack);%freq(MARITAL_STATUS); %freq(GENDER); %freq(femalesex); 
%stat(LOS);%stat(LOS,stat=mediqr);%freq(losgt31); %freq(Acute_resp_failure); 
%freq(Acute_Renal_Failure); 
 
%freq(pvd);  %freq(anticoag_hep);  %freq(dm); %freq(dialysis); 
%freq(hx_arrest); %freq(hx_cabg); %freq(Hx_CAD); %freq(Cardio_shock); 
%freq(CBVD); %freq(CKD); 
%freq(LungDisease); %freq(Dementia); %freq(Dialysis_diag); %freq(Dm_Pr_Sec); 
%freq(Dm_Pr);  
%freq(End_Stage_Renal_Disease); %freq(Ty2_dm); %freq(Ty1_dm); %freq(Dyslip); 
%freq(HF); %freq(syst_hf); 
%freq(dias_hf); %freq(comb_hf); %freq(oth_hf); %freq(HTN); %freq(hx_pci); 
%freq(Kidney_Transplant); 
%freq(liver_dis); %freq(PriorMI); %freq(PVD1); %freq(Any_shock); 
%freq(Other_Shock); %freq(Sep_Shock); 
%freq(Smoking); %freq(Stroke_TIA); %freq(hx_stroke_Tia); %freq(Stemi); 
%freq(Nstemi); %freq(unknown_ami); 
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%freq(Unstable_Angina); %freq(Stable_Angina); %freq(ace_inhibit); 
%freq(anticoagulant); %freq(anti_plate); 
%freq(arb); %freq(aspirin); %freq(aspirin_dipyridamole); %freq(bblk); 
%freq(bronchodilators); %freq(ccb); 
%freq(dipyridamole); %freq(diuretics); %freq(gp2a3b); %freq(heparin); 
%freq(insulin); %freq(long_insulin); 
%freq(short_insulin); %freq(lipid_lowering); %freq(nsaids); %freq(nitrate); 
%freq(oral); %freq(plat_inhibit); 
%freq(statin); %freq(thrombolytics); %freq(warfarin); 
%freq(Coronary_Angiography); %freq(AVR_MVR); %freq(Cath); 
%freq(PCI);%freq(cathpci);  %freq(CABG); %freq(dialysis_proc); 
%freq(mech_vent); %freq(PVD2); 
 
%freq(bival); 
 
%stat(adm_cr,stat=mediqr,ndec=2);%stat(adm_cr); 
%stat(mean_cr,stat=mediqr,ndec=2);  
%stat(adm_glucose,stat=mediqr,ndec=2); 
%stat(mean_glucose,stat=mediqr,ndec=2); 
%stat(num_glucose); %stat(num_glucose,stat=mediqr);  
%freq(max_cr,stat=mediqr,ndec=2); %freq(num_cr,stat=mediqr,ndec=2); 
%freq(iv_insulin2,stat=mediqr,ndec=2);  
 
 
%stat(NCR40);  
 
%stat(first_hct,stat=mediqr,ndec=2); %stat(first_hgb,stat=mediqr,ndec=2);  
%stat(first_trop,stat=mediqr,ndec=2); %stat(first_wbc,stat=mediqr,ndec=2); 
%stat(first_ckmb,stat=mediqr,ndec=2); 
 
 %stat(GFR_MDRD4_Init_BC,stat=mediqr,ndec=2);  
%stat(adm_cr,stat=mediqr,ndec=2); %stat(max_cr,stat=mediqr,ndec=2);  
 
 %freq(hospdeath); %freq(death24hr); 
 
%freq(AKI); %freq(acearb);  
 
%endtable; 
%endreport; 
ods rtf close;  
 
 
ods rtf file="C:\Documents and Settings\p08806\Desktop\KU MS-CR 
Classes\Thesis Materials\table1 &rundate..rtf";  
 
 
*missing data for model covariates??? ; 
 
proc contents data=phleb.bw_091610 varnum ; run;  
 
ods rtf file="C:\Documents and Settings\p08806\Desktop\KU MS-CR 
Classes\Thesis Materials\missingness of predictors &rundate..rtf";  
 
title 'missingness of predictors'; 
proc means data=phleb.bw_091610 n nmiss min max ndec=0; 
var age femalesex caucasian 
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stemi acute_renal_failure num_phleb_labs heparin cardio_shock cathpci gp2a3b 
bival 
 anti_plate aspirin thrombolytics ckd adm_cr  priormi dm hf htn totalml 
mild_anemia mod_anemia sev_anemia  smoking  adm_hgb  thrombolytics mech_vent 
lungdisease cath pci  
gp2a3b bival heparin aspirin anti_plate bblk statin acearb totalml hospdeath 
haa modsevhaa bleeding_event; 
run; 
 
ods rtf close;  
 
*got a help with the following as I do not have multiple imputation software 
or know how to do it; 
/* 
* impute missing creatinine values and a few other missing ; 
 
data modelvars; 
set phleb.bw_091610; 
keep  patient_nbr hospital_id  
haa mild_anemia mod_anemia sev_anemia modsev_vs_mildnone hospdeath 
age femalesex caucasian 
stemi acute_renal_failure num_phleb_labs heparin cardio_shock cathpci gp2a3b 
bival 
 anti_plate aspirin thrombolytics ckd adm_cr  priormi dm hf htn totalml 
mild_anemia mod_anemia sev_anemia  smoking  adm_hgb  thrombolytics mech_vent 
lungdisease cath pci  
gp2a3b bival heparin aspirin anti_plate bblk statin acearb totalml hospdeath 
haa modsevhaa bleeding_event    ; 
run; 
 
 
options set = SRCLIB 'C:\Work\SAS\addons\iveware\ive_sas_windows' 
sasautos=('!srclib' sasautos);  
 
data _null_; 
  file "impute.set"; 
  put "title imputation;"; 
  put "datain modelvars;"; 
  put "dataout phleb.bw_imputed_091610 all;"; 
  put "default categorical;"; 
  put "continuous age num_phleb_labs totalml adm_hgb adm_cr;"; 
  put "transfer patient_nbr hospital_id;"; 
  put "iterations 2;"; 
  put "multiples 1;"; 
  put "seed 20071205;"; 
  put "run;"; 
run; 
   
* use IVEWARE to impute ;  
%impute(name=impute, dir=.); 
 
data phleb.bw_imputed_091610 ; 
set phleb.bw_imputed_091610 ; 
if adm_cr<0 then adm_cr=0; 
run; 
*/  
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title 'missingness of predictors after imputation'; 
proc means data=phleb.bw_imputed_091610  n nmiss min max ndec=0; 
var age femalesex caucasian 
stemi acute_renal_failure num_phleb_labs heparin cardio_shock cathpci gp2a3b 
bival 
 anti_plate aspirin thrombolytics ckd adm_cr  priormi dm hf htn totalml 
mild_anemia mod_anemia sev_anemia  smoking  adm_hgb  thrombolytics mech_vent 
lungdisease cath pci  
gp2a3b bival heparin aspirin anti_plate bblk statin acearb totalml hospdeath 
haa modsevhaa  hospital_id; 
run; 
 
 
 
*                    HAA models                        ;  
 
*model without covariates to get unadjusted RRs accounting only for site; 
 
title 'predictors of moderate/severe HAA'; 
title2 'hierarchicial modified poisson model'; 
title3 'variables are site centered, random site effect ';  
title4 '******** unadjusted RR for phlebotomy and mod/sev HAA 
**************';  
proc glimmix data=phleb.bw_imputed_091610   empirical ; 
 class hospital_id ; 
   model modsev_vs_mildnone =   totalml_  / dist=poisson link=log ; 
 estimate 'Total phlebotomy ml (50 ml increase)' totalml_w 50 /exp cl; 
random int / subject=hospital_id ;  
  nloptions tech=trureg /*(or nrridg) */ maxiter=1000;  
run; 
 
title 'model results predicting moderate/severe HAA '; 
title2 'modified poisson model, relative risks'; 
proc print data=haaest2; 
var label expestimate explower expupper probt;  
run; 
 
 
title 'model results predicting HAA '; 
title2 'modified poisson model, relative risks'; 
proc print data=haaest; 
var label expestimate explower expupper probt;  
run; 
 
*multivariable model; 
 
title 'predictors of moderate/severe HAA'; 
title2 'hierarchicial modified poisson model'; 
title3 'variables are site centered, random site effect ';  
 
ods graphics on; 
ods rtf file="C:\Documents and Settings\p08806\Desktop\KU MS-CR 
Classes\Thesis Materials\plots.rtf";  
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proc glimmix data=phleb.bw_imputed_091610;  
    class hospital_id; 
    model modsev_vs_mildnone =  age femalesex caucasian stemi 
acute_renal_failure totalml heparin cardio_shock cathpci gp2a3b bival 
  anti_plate  bblk statin acearb aspirin thrombolytics mech_vent 
ckd priormi dm hf htn 
         / dist=poisson link=log ; 
 estimate 'Age (10 year increase)' age 10 /exp cl; 
 estimate 'Female' femalesex 1 /exp cl; 
 estimate 'Non-Caucasian' caucasian -1 /exp cl; 
 estimate 'ST elevation MI' stemi 1 /exp cl; 
 estimate 'Acute Renal Failure' acute_renal_failure 1 /exp cl; 
 estimate 'Heparin' heparin 1 /exp cl; 
 estimate 'Cardiogenic Shock' cardio_shock 1 /exp cl; 
 estimate 'In hospital Cath or PCI' cathpci 1 /exp cl; 
 estimate 'Gp2a3b' gp2a3b 1 /exp cl; 
 estimate 'Bivalirudin' bival 1 /exp cl; 
 estimate 'Antiplatelet' anti_plate 1 /exp cl; 
 estimate 'Beta-Blocker' bblk 1 /exp cl; 
 estimate 'Statin' statin 1 /exp cl; 
 estimate 'ACE/ARB' acearb 1 /exp cl; 
 estimate 'Aspirin' aspirin 1 /exp cl; 
 estimate 'Thrombolytics' thrombolytics 1 /exp cl; 
 estimate 'Mechanical ventilation' mech_vent 1 /exp cl; 
 estimate 'CKD' ckd 1 /exp cl;  
 estimate 'Prior MI' priormi 1 /exp cl; 
 estimate 'Diabetes' dm 1 /exp cl; 
 estimate 'Heart failure' hf 1 /exp cl; 
 estimate 'Hypertension' htn 1 /exp cl; 
 estimate 'Total phlebotomy ml (50 ml increase)' totalml 50 /exp cl; 
 random int / subject=hospital_id ;   
  nloptions tech=trureg /*(or nrridg) */ maxiter=1000;  
ods output estimates=haaest2; 
output out=pred2 pred(ilink blup)=pred; 
 
run; 
ods rtf close; 
ods graphics off; 
 
*assessing calibration of model - mean within each decile of predicted vs. 
observed; 
 
%cut(data=pred2,var=pred,ngroups=10,cutvar=decile); 
 
 
proc sort data=pred2; 
 
by decile; 
 
run; 
 
proc means data=pred2; 
 
var modsev_vs_mildnone pred; 
 
by decile; 
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output out=calibplot; 
 
run; 
 
proc freq dataq=pred2; 
 
tables decile; 
 
run; 
 
data calibplot; set calibplot; 
 
if _stat_ = 'MEAN'; 
 
run; 
 
title 'Calibration plot'; 
 
data anno; 
 
function='move'; xsys='1'; ysys='1'; x=0; y=0; output; 
 
function='draw'; xsys='1'; ysys='1'; color='red'; x=100; y=100; output; 
 
run; 
 
  
 
proc gplot data=calibplot; 
 
plot modsev_vs_mildnone*pred/anno=anno haxis=axis1 vaxis=axis2;; 
 
plot y=x; 
 
run;quit;  
 
 
 
run; 
 
 
 
* we generated the figures with R - this macro will not work on my laptop, 
only at SLH; 
 
%r(data=haaest2,cmd=source('C:\\work\\R\\functions.r'); 
 library(biostat);  
  win.metafile("C:\\work\\salisbury\\phlebotomy in health facts\\2010-9-
16\\forest plot model results predicting modsev HAA 
&rundate....wmf",width=9,height=10,pointsize=15); 
  
forestplot(expestimate,explower,expupper,label,col.ref='red',frame=F,log=T,xl
im=c(.5,3.5),ann='right',interp=c('<<<< Lower Risk','Higher Risk 
>>>>'),cex.interp=.9,digits.ann=2,xlab='',lwd.ref=2,lwd.est=2); 
dev.off(); 
); 
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ods rtf file="C:\Documents and Settings\p08806\Desktop\KU MS-CR 
Classes\Thesis Materials\model results predicting HAA &rundate..rtf";  
 
 
*used our groups C statistic macro; 
 
title 'C-statistic for model results predicting HAA'; 
title2 'modified poisson model, relative risks'; 
/*   GET THE C STATISTIC  HAA model */ 
 data predout; 
 set pred; run; 
/* THEN RUN THE FOLLOWING CODE.   
   C-STATISTIC WILL PRINT OUT IN THE OUTPUT WINDOW */ 
proc iml; 
*reset print; 
  use predout; 
  /* CHANGE VARIABLE NAMES IN PARENTHESES TO ACTUAL AND PREDICTED */ 
  read all var {haa} into y; *vector of binary outcomes*; 
  read all var {Pred} into x; *vector of predictor variable*; 
  x1 = x[loc(y = 0 & x ^= .),]; **predvar values corresponding to y = 0**; 
  x2 = x[loc(y = 1 & x ^= .),];  **predvar values corresponding to y = 1**; 
  n1 = nrow(x1); 
  n2 = nrow(x2); 
  concordant = 0; ties = 0; discordant = 0; **initialize**; 
  do i = 1 to n1; 
    do j = 1 to n2; 
   concordant = concordant + (x1[i] < x2[j]); 
   discordant = discordant + (x1[i] > x2[j]); 
   ties = ties + (x1[i] = x2[j]); 
 end; 
  end; 
    cstat = (concordant + .5*ties)/(n1*n2); 
print cstat concordant discordant ties; 
quit; 
 
 
 
 
title 'C-statistic for model predicting moderate/severe HAA (BW)'; 
title2 'modified poisson model, relative risks'; 
/*   GET THE C STATISTIC  HAA model */ 
 data predout2; 
 set pred2; run; 
/* THEN RUN THE FOLLOWING CODE.   
   C-STATISTIC WILL PRINT OUT IN THE OUTPUT WINDOW */ 
proc iml; 
*reset print; 
  use predout2; 
  /* CHANGE VARIABLE NAMES IN PARENTHESES TO ACTUAL AND PREDICTED */ 
  read all var {modsev_vs_mildnone} into y; *vector of binary outcomes*; 
  read all var {Pred} into x; *vector of predictor variable*; 
  x1 = x[loc(y = 0 & x ^= .),]; **predvar values corresponding to y = 0**; 
  x2 = x[loc(y = 1 & x ^= .),];  **predvar values corresponding to y = 1**; 
  n1 = nrow(x1); 
  n2 = nrow(x2); 
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  concordant = 0; ties = 0; discordant = 0; **initialize**; 
  do i = 1 to n1; 
    do j = 1 to n2; 
   concordant = concordant + (x1[i] < x2[j]); 
   discordant = discordant + (x1[i] > x2[j]); 
   ties = ties + (x1[i] = x2[j]); 
 end; 
  end; 
    cstat = (concordant + .5*ties)/(n1*n2); 
print cstat concordant discordant ties; 
quit; 
 
ods rtf close; 
 
 
*test for interaction between gender and phlebotomy volume; 
 
 
title 'predictors of moderate/severe HAA'; 
title2 'hierarchicial modified poisson model'; 
title3 'variables are site centered, random site effect ';  
proc glimmix data=phleb.bw_imputed_091610   empirical ; 
 class hospital_id ; 
   model modsev_vs_mildnone =  age_w femalesex_w caucasian_w 
  stemi_w acute_renal_failure_w totalml_w heparin_w cardio_shock_w 
cathpci_w gp2a3b_w bival_w 
  anti_plate_w  bblk_w statin_w acearb_w aspirin_w thrombolytics_w 
mech_vent_w ckd_w priormi_w dm_w hf_w htn_w   
   totalml_w* femalesex_w 
/ dist=poisson link=log ; 
random int / subject=hospital_id ;  
  nloptions tech=trureg /*(or nrridg) */ maxiter=1000;  
run; 
 
 
proc glimmix data=phleb.bw_imputed_091610   empirical ; 
 class hospital_id ; 
   model modsev_vs_mildnone =  age_w  caucasian_w 
  stemi_w acute_renal_failure_w totalml_w heparin_w cardio_shock_w 
cathpci_w gp2a3b_w bival_w 
  anti_plate_w  bblk_w statin_w acearb_w aspirin_w thrombolytics_w 
mech_vent_w ckd_w priormi_w dm_w hf_w htn_w   
   bleeding_event  
   / dist=poisson link=log ; 
estimate 'Total phlebotomy ml (50 ml increase)' totalml_w 50 /exp cl; 
random int / subject=hospital_id ;  
  nloptions tech=trureg /*(or nrridg) */ maxiter=1000;  
  where femalesex=1;  
run; 
 
*so RR for 50 ml of diagnostic blood loss among females is 1.12; 
 
proc glimmix data=phleb.bw_imputed_091610   empirical ; 
 class hospital_id ; 
   model modsev_vs_mildnone =  age_w  caucasian_w 
  stemi_w acute_renal_failure_w totalml_w heparin_w cardio_shock_w 
cathpci_w gp2a3b_w bival_w 
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  anti_plate_w  bblk_w statin_w acearb_w aspirin_w thrombolytics_w 
mech_vent_w ckd_w priormi_w dm_w hf_w htn_w   
   bleeding_event  
   / dist=poisson link=log ; 
estimate 'Total phlebotomy ml (50 ml increase)' totalml_w 50 /exp cl; 
random int / subject=hospital_id ;  
  nloptions tech=trureg /*(or nrridg) */ maxiter=1000;  
  where femalesex=0;  
run; 
 
*and RR for 50 ml of diagnostic blood loss among males is 1.15; 
*this is not a large difference even if the risk was applied across 100-150 
ml increments, accordingly, this 
interaction seems statistically significant but clinically insignificant.  I 
left it out of the final model; 
 
 
*next step is understanding the proportion that develop HAA on each hospital 
day out of the  
total at risk - ie, on hospital day #1, how many develop HAA?  then throw out 
the patients with 
HAA and determine the proportion of those w/o HAA at the start of day 2 
develop HAA on day 2, and so 
on; 
*thanks to Kimberly for help with the data step/proc sql on this; 
 
proc sort data=phleb.bw_091610; by patient_nbr; run;  
 
/* transpose data to vertical days for los for each patient */  
data modsevHAA; 
set phleb.BW_091610; 
timetohaa_modsev = floor(timetohaa_modsev);  
if timetohaa_modsev=0 then timetohaa_modsev=1;  
format timetohaa_modsev 2.0;  
keep patient_nbr modsevhaa timetohaa_modsev bleeding_event; 
run; 
 
 
data los; 
set phleb.BW_091610; 
los = floor(los);  
if los=0 then los=1;  
format los 2.0;  
if los^=.;  
keep patient_nbr los ; 
run; 
 
data verticallos; 
set los; 
 do i= 1 to los;  
  day=i ;  
  output ; 
 end; 
drop i;  
run; 
 
proc sql; 
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create table both as select * 
from verticallos as a 
left join modsevHAA as b  
on a.patient_nbr = b.patient_nbr ; 
quit;  
 
proc sort data=both; by patient_nbr day; run;  
 
 
* only keep records up until devlopment of mod sev HAA ; 
data time; 
set both; 
if (modsevhaa=1 and day<= timetohaa_modsev) or modsevhaa=0 ; 
run; 
 
 
ods rtf file="C:\Work\Salisbury\phlebotomy in health facts\2010-9-16\Time to 
development of HAA &rundate..rtf";  
 
title 'Time to development of moderate/severe HAA by day in hospital';  
proc freq data=time ; 
tables     day*modsevhaa ; 
run; 
 
title 'Time to development of moderate/severe HAA by day in hospital';  
title2 ' among those without a bleeding event';  
proc freq data=time ; 
tables     day*modsevhaa ; 
where bleeding_event=0;  
run; 
 
ods rtf close;  
 
*ml of phlebotomy on each day of hospital stay both median and mean; 
 
title 'median and IQR of blood drawn per day (up through 10th day)';  
proc means data= phleb.BW_analysis_091610 n q1 median q3  ndec=1; 
var  TotalmlDay1 TotalmlDay2 TotalmlDay3 TotalmlDay4 TotalmlDay5 TotalmlDay6 
TotalmlDay7 TotalmlDay8 
TotalmlDay9 TotalmlDay10 ; 
run; 
 
title 'mean and stddev of blood drawn per day (up through 10th day)';  
title2 'among those without bleeding events';  
proc means data= phleb.BW_analysis_091610 n mean stddev  ndec=1; 
var TotalmlDay1 TotalmlDay2 TotalmlDay3 TotalmlDay4 TotalmlDay5 TotalmlDay6 
TotalmlDay7 TotalmlDay8 
TotalmlDay9 TotalmlDay10;where bleeding_event=0; 
run; 
 
 
 
